Clinafloxacin Pharmacokinetics in Subjects with Various Degrees of Renal Function
AUTOR(ES)
Randinitis, Edward J.
FONTE
American Society for Microbiology
RESUMO
As the primary route for elimination of clinafloxacin is renal clearance (CLR) of unchanged drug, studies were conducted to determine the pharmacokinetic profile of clinafloxacin following administration to young and elderly subjects, subjects with various degrees of renal function, and subjects requiring dialysis. These were open-label studies in which subjects received single oral clinafloxacin doses. Sixteen young subjects (18 to 35 years old) and 16 elderly subjects (>65 years old) were enrolled in a study comparing pharmacokinetic profiles of clinafloxacin in young and elderly subjects. Twenty subjects having various degrees of renal function were enrolled into one of three groups based on degree of renal function as measured by creatinine clearance (CLCR). Twelve subjects with severe renal impairment requiring dialysis enrolled in a third study. Clinafloxacin was generally well tolerated by all subjects. Clinafloxacin pharmacokinetic profiles in elderly subjects were dependent only on age-related decreases in renal function. Clinafloxacin maximum concentrations in plasma, areas under the concentration-time curves, and terminal elimination half-life values increased with decreasing CLCR values. Total apparent body clearance of clinafloxacin from the plasma after oral administration (CLoral) and CLR were dependent on CLCR according to the following relationships: CLoral = 2.3 · CLCR + 77 and CLR = 1.74 · CLCR. Hemodialysis had no significant effect on clinafloxacin clearance. Based on the relationship between CLCR and clinafloxacin CLoral and CLR values, the clinafloxacin dose should be halved in patients having a CLCR of <40 ml/min. Further dose adjustment is not warranted in patients requiring hemodialysis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90689Documentos Relacionados
- Pharmacokinetics of piperacillin in subjects with various degrees of renal function.
- Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
- Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
- Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
- Vancomycin pharmacokinetics in patients with various degrees of renal function.